Immatics Biotechnologies GmbH, announced today a comprehensive data set having completed the first cohort of the ACTolog® Personalized Multi-Target T-cell Therapy Trial (Study code: IMA101-101, NCT02876510) at the AACR Special Conference on Immune Cell Therapies for Cancer.
Immatics Presents First Cohort Data on the ACTolog® Personalized Multi-Target Cell Therapy Trial Demonstrating Safety and T-cell Persistence in Treated Cancer Patients
Immatics Appoints Harpreet Singh as Chief Executive Officer
Immatics Biotechnologies GmbH, today announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer.
Harpreet Singh has most recently been President and CEO of Immatics US and Chief Scientific Officer of the Company, having co-founded Immatics. He has been instrumental in growing the Company from a start-up to a leading player in the field of immuno-oncology.
Immatics Initiates Third Phase I Clinical Trial of its Unique ACTengine® Platform in Patients with Advanced Solid Cancers
Immatics, today announced that it has initiated enrollment of patients into a phase I trial of IMA203, its third T-cell receptor (TCR)-transduced adoptive cell therapy program. IMA203 is an investigational immunotherapy which uses Immatics’ proprietary ACTengine® approach and is based on genetic engineering of the patient’s own T cells to express an exogenous TCR. The goal is to redirect and activate the T cells to treat solid tumors.